Maxim Group analyst Jason McCarthy maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $45 to $20.
Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.